Highlights

  • Chimeric Therapeutics reported early tumour-shrinkage data from the highest dose level tested in its CHM CDH17 CAR-T trial.
  • Two of four patients at Dose Level 3 showed individual lesion shrinkage between 17% and 40%.
  • The Phase 1/2 study remains early-stage, with additional patient dosing dependent on funding availability.
  • Chimeric raised approximately $2.27 million in July 2026 following a June quarter cash balance of about $0.8 million.

Chimeric Therapeutics (ASX:CHM) has reported early tumour-shrinkage data from the highest dose tested so far in its CHM CDH17 CAR-T cell therapy trial, with two of four patients showing individual lesion shrinkage between 17% and 40%.

The data, released on 16 July 2026, comes from an ongoing Phase 1/2 dose-escalation study evaluating patients with advanced gastrointestinal cancers who have previously exhausted standard treatment options.

The results represent an early clinical signal rather than a confirmed efficacy outcome, with only four patients treated at the highest dose level and the study still in progress. For Chimeric (ASX:CHM), the update provides additional information on the development pathway for its solid-tumour CAR-T program while the company continues a strategic review and manages funding requirements.

What Was Announced?

CHM CDH17, also known as CHM-2101, is an autologous third-generation CAR-T cell therapy developed using a patient's own T-cells, which are genetically modified to recognise and target cells expressing the CDH17 biomarker.

CDH17 is found in several gastrointestinal cancers, including colorectal cancer, gastric cancer and intestinal neuroendocrine tumours.

The therapy is being evaluated in a Phase 1/2 dose-escalation study, where groups of patients receive increasing doses to assess safety before broader efficacy evaluation.

The July update relates to Dose Level 3, which involves 450 million CAR-T cells and represents the highest dose tested to date. Four patients have received treatment at this dose level.

Two patients showed preliminary tumour response data, with individual lesion shrinkage ranging from 17% to 40%. One patient maintained stable disease for six months, while another maintained stable disease for four months.

A fifth patient has completed cell Manufacturing and is expected to receive treatment, while a sixth Dose Level 3 patient is targeted by the end of 2026, subject to funding.

The company reported one dose-limiting toxicity event on 31 May 2026, with no further safety signals identified since that event.

Why This Matters

CAR-T therapies have demonstrated clinical benefits in some blood cancers but have faced challenges in solid tumours due to tumour environments, target selection and treatment persistence.

For Chimeric (ASX:CHM), any tumour response signal in a solid-tumour CAR-T program provides additional information around the potential applicability of the technology in a more difficult treatment setting.

The current trial focuses on patients with advanced gastrointestinal cancers who have limited treatment Options after standard therapies. If future studies demonstrate consistent and durable responses, the platform could support further development or potential partnering discussions.

However, the current dataset remains limited, with only a small number of treated patients and no regulatory submission or approval pathway established.

Company Background

Chimeric Therapeutics is an Australian clinical-stage biotechnology company focused on developing cell therapies for cancer.

Its lead solid-tumour program is CHM CDH17, which uses licensed academic technology originating from the University of Pennsylvania.

The company has previously disclosed Fast Track Designation from the U.S. Food and Drug Administration (FDA) for CHM CDH17. The designation is intended to support development and review processes for treatments addressing serious conditions with unmet medical need but does not guarantee regulatory approval.

Financial Position

Chimeric ended the June 2026 quarter with cash of approximately $0.8 million.

The company subsequently raised approximately $2.27 million in July 2026, bringing combined available cash to around $3.07 million.

During the quarter, Chimeric completed a 1-for-100 share consolidation and disclosed the retirement of an independent non-executive director after the quarter ended.

On 1 July 2026, the board announced a strategic review and appointed Hawkesbury Partners as independent financial adviser to assess potential strategic options.

The review may consider options including partnerships, asset transactions, mergers or other corporate outcomes, although no conclusion timeline has been disclosed.

What Comes Next?

Chimeric's immediate clinical focus is dosing additional Dose Level 3 patients, with a fifth patient expected to be treated and a sixth patient targeted by the end of 2026, subject to funding.

The company will continue monitoring patient outcomes through standard follow-up assessments at 28 and 90 days after treatment.

The strategic review led by Hawkesbury Partners is also ongoing and could influence the company's future structure or development pathway.

Future updates are expected around patient dosing, follow-up clinical data and any developments from the strategic review process.

Risks

Chimeric (ASX:CHM) faces funding risk, with additional patient dosing dependent on available Capital and the possibility of future dilution or strategic transactions. The clinical dataset remains limited, with tumour shrinkage data based on only two patients at the highest dose level. Early responses may not translate into durable treatment effects or regulatory success, particularly given the challenges associated with solid-tumour CAR-T development. Safety at the current dose level also requires further monitoring following the reported dose-limiting toxicity event.

Investor Takeaway

The latest CHM CDH17 update provides early clinical information from a difficult treatment area, with two patients showing individual lesion shrinkage at the highest tested dose level.

However, the findings remain preliminary and are based on a small patient group. For Chimeric (ASX:CHM), the next important developments include additional patient dosing, follow-up efficacy and safety data, funding management and the outcome of the ongoing strategic review.

The ability to progress the program while maintaining financial flexibility will remain a key Factor as the company advances its CAR-T platform.